14
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Centrilobular emphysema and coronary artery calcification: mediation analysis in the SPIROMICS cohort

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Chronic obstructive pulmonary disease (COPD) is associated with a two-to-five fold increase in the risk of coronary artery disease independent of shared risk factors. This association is hypothesized to be mediated by systemic inflammation but this link has not been established.

          Methods

          We included 300 participants enrolled in the SPIROMICS cohort, 75 each of lifetime non-smokers, smokers without airflow obstruction, mild-moderate COPD, and severe-very severe COPD. We quantified emphysema and airway disease on computed tomography, characterized visual emphysema subtypes (centrilobular and paraseptal) and airway disease, and used the Weston visual score to quantify coronary artery calcification (CAC). We used the Sobel test to determine whether markers of systemic inflammation mediated a link between spirometric and radiographic features of COPD and CAC.

          Results

          FEV 1/FVC but not quantitative emphysema or airway wall thickening was associated with CAC ( p = 0.036), after adjustment for demographics, diabetes mellitus, hypertension, statin use, and CT scanner type. To explain this discordance, we examined visual subtypes of emphysema and airway disease, and found that centrilobular emphysema but not paraseptal emphysema or bronchial thickening was independently associated with CAC ( p = 0.019). MMP3, VCAM1, CXCL5 and CXCL9 mediated 8, 8, 7 and 16% of the association between FEV 1/FVC and CAC, respectively. Similar biomarkers partially mediated the association between centrilobular emphysema and CAC.

          Conclusions

          The association between airflow obstruction and coronary calcification is driven primarily by the centrilobular subtype of emphysema, and is linked through bioactive molecules implicated in the pathogenesis of atherosclerosis.

          Trial Registration

          ClinicalTrials.gov: Identifier: NCT01969344.

          Electronic supplementary material

          The online version of this article (10.1186/s12931-018-0946-1) contains supplementary material, which is available to authorized users.

          Related collections

          Most cited references41

          • Record: found
          • Abstract: found
          • Article: not found

          A major role for VCAM-1, but not ICAM-1, in early atherosclerosis.

          VCAM-1 and ICAM-1 are endothelial adhesion molecules of the Ig gene superfamily that may participate in atherogenesis by promoting monocyte accumulation in the arterial intima. Both are expressed in regions predisposed to atherosclerosis and at the periphery of established lesions, while ICAM-1 is also expressed more broadly. To evaluate functions of VCAM-1 in chronic disease, we disrupted its fourth Ig domain, producing the murine Vcam1(D4D) allele. VCAM-1(D4D) mRNA and protein were reduced to 2-8% of wild-type allele (Vcam1(+)) levels but were sufficient to partially rescue the lethal phenotype of VCAM-1-null embryos. After crossing into the LDL receptor-null background, Vcam1(+/+) and Vcam1(D4D/D4D) paired littermates were generated from heterozygous intercrosses and fed a cholesterol-enriched diet for 8 weeks. The area of early atherosclerotic lesions in the aorta, quantified by en face oil red O staining, was reduced significantly in Vcam1(D4D/D4D) mice, although cholesterol levels, lipoprotein profiles, and numbers of circulating leukocytes were comparable to wild-type. In contrast, deficiency of ICAM-1 either alone or in combination with VCAM-1 deficiency did not alter nascent lesion formation. Therefore, although expression of both VCAM-1 and ICAM-1 is upregulated in atherosclerotic lesions, our data indicate that VCAM-1 plays a dominant role in the initiation of atherosclerosis.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            CT-Definable Subtypes of Chronic Obstructive Pulmonary Disease: A Statement of the Fleischner Society.

            The purpose of this statement is to describe and define the phenotypic abnormalities that can be identified on visual and quantitative evaluation of computed tomographic (CT) images in subjects with chronic obstructive pulmonary disease (COPD), with the goal of contributing to a personalized approach to the treatment of patients with COPD. Quantitative CT is useful for identifying and sequentially evaluating the extent of emphysematous lung destruction, changes in airway walls, and expiratory air trapping. However, visual assessment of CT scans remains important to describe patterns of altered lung structure in COPD. The classification system proposed and illustrated in this article provides a structured approach to visual and quantitative assessment of COPD. Emphysema is classified as centrilobular (subclassified as trace, mild, moderate, confluent, and advanced destructive emphysema), panlobular, and paraseptal (subclassified as mild or substantial). Additional important visual features include airway wall thickening, inflammatory small airways disease, tracheal abnormalities, interstitial lung abnormalities, pulmonary arterial enlargement, and bronchiectasis.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Computed tomographic measurements of airway dimensions and emphysema in smokers. Correlation with lung function.

              Chronic obstructive pulmonary disease (COPD) is characterized by the presence of airflow obstruction caused by emphysema or airway narrowing, or both. Low attenuation areas (LAA) on computed tomography (CT) have been shown to represent macroscopic or microscopic emphysema, or both. However CT has not been used to quantify the airway abnormalities in smokers with or without airflow obstruction. In this study, we used CT to evaluate both emphysema and airway wall thickening in 114 smokers. The CT measurements revealed that a decreased FEV(1) (%predicted) is associated with an increase of airway wall area and an increase of emphysema. Although both airway wall thickening and emphysema (LAA) correlated with measurements of lung function, stepwise multiple regression analysis showed that the combination of airway and emphysema measurements improved the estimate of pulmonary function test abnormalities. We conclude that both CT measurements of airway dimensions and emphysema are useful and complementary in the evaluation of the lung of smokers.
                Bookmark

                Author and article information

                Contributors
                205-934-6148 , sbhatt@uabmc.edu
                Journal
                Respir Res
                Respir. Res
                Respiratory Research
                BioMed Central (London )
                1465-9921
                1465-993X
                18 December 2018
                18 December 2018
                2018
                : 19
                : 257
                Affiliations
                [1 ]ISNI 0000000106344187, GRID grid.265892.2, Division of Pulmonary, Allergy and Critical Care Medicine and Lung Health Center, , University of Alabama at Birmingham, ; THT 422, 1720, 2nd Avenue South, Birmingham, AL 35294 USA
                [2 ]ISNI 0000000106344187, GRID grid.265892.2, UAB Lung Imaging Core, , University of Alabama at Birmingham, ; Birmingham, AL 35294 USA
                [3 ]ISNI 0000000106344187, GRID grid.265892.2, Department of Radiology, , University of Alabama at Birmingham, ; Birmingham, AL 35294 USA
                [4 ]ISNI 0000000106344187, GRID grid.265892.2, Department of Preventive Medicine, , University of Alabama at Birmingham, ; Birmingham, AL 35294 USA
                [5 ]ISNI 0000 0001 2297 6811, GRID grid.266102.1, Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, , University California San Francisco, ; San Francisco, CA 94143 USA
                [6 ]Birmingham Veterans Affairs Hospital, Birmingham, AL 35294 USA
                [7 ]ISNI 0000 0001 2285 2675, GRID grid.239585.0, Division of Pulmonary, Allergy and Critical Care Medicine, , Columbia University Medical Center, ; New York, NY 10032 USA
                [8 ]ISNI 0000000086837370, GRID grid.214458.e, Division of Pulmonary and Critical Care Medicine, , University of Michigan, ; Ann Arbor, MI 48109 USA
                [9 ]ISNI 0000 0004 1936 8753, GRID grid.137628.9, Division of Pulmonary and Critical Care Medicine, , Weill Cornell School of Medicine, ; New York, NY 10065 USA
                Author information
                http://orcid.org/0000-0002-8418-4497
                Article
                946
                10.1186/s12931-018-0946-1
                6299495
                30563576
                56c5da62-f4ae-4d39-8059-e1e3544c3daf
                © The Author(s). 2018

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 5 July 2018
                : 20 November 2018
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/100000050, National Heart, Lung, and Blood Institute;
                Award ID: K23HL133438
                Award ID: HHSN268200900013C
                Award ID: HHSN268200900014C
                Award ID: HHSN268200900015C
                Award ID: HHSN268200900016C
                Award ID: HHSN268200900017C
                Award ID: HHSN268200900018C
                Award ID: HHSN268200900019C
                Award ID: HHSN268200900020C
                Award Recipient :
                Categories
                Research
                Custom metadata
                © The Author(s) 2018

                Respiratory medicine
                emphysema,copd,coronary artery calcification,cardiovascular disease,mediators
                Respiratory medicine
                emphysema, copd, coronary artery calcification, cardiovascular disease, mediators

                Comments

                Comment on this article